Evaluation of an inhibitor of DNA methylation, 5-aza-2'-deoxycytidine, for the treatment of lung cancer and the future role of gene therapy.
Momparler
R L
RL
Département de pharmacologie, Université de Montréal, Centre de recherche pédiatrique, Hôpital Ste-Justine, Côte Ste-Catherine, Montréal, Québec, Canada.
Eliopoulos
N
N
Ayoub
J
J
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000493:pharmacokinetics / Q000494:pharmacology*; D001374:Azacitidine / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000494:pharmacology; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000628:therapy*; D019175:DNA Methylation / Q000187:drug effects; D015254:DNA Modification Methylases / Q000037:antagonists & inhibitors*; D000077209:Decitabine; D005069:Evaluation Studies as Topic; D005544:Forecasting; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000628:therapy*
D000903:Antibiotics, Antineoplastic; D000077209:Decitabine; D015254:DNA Modification Methylases; D001374:Azacitidine